Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CXCR4


Brief Information

Name:C-X-C motif chemokine receptor 4
Target Synonym:NPYRL,CD184,CXCR4,CXC-R4,SDF-1 receptor,LAP-3,Fusin,FB22,HM89,Seven-Transmembrane-Segment Receptor, Spleen,Chemokine (C-X-C Motif), Receptor 4 (Fusin),Seven Transmembrane Helix Receptor,C-X-C Chemokine Receptor Type 4,Neuropeptide Y Receptor Y3,Neuropeptide Y3 Receptor,Chemokine Receptor,D2S201E,HSY3RR,NPYY3R,CXCR-4,NPY3R,WHIMS,LAP3,NPYR,WHIM,Receptors, CXCR4,LCR1,LESTR,LPS-associated protein 3,Leukocyte-Derived Seven Transmembrane Domain Receptor,Stromal Cell-Derived Factor 1 Receptor,Chemokine
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:25
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CX4-H5219 Human Human CXCR4 / CD184 Full Length Protein (VLP)
CX4-H5269 Human Human CXCR4 / CD184 Protein, Fc Tag
ACRO Quality

Part of Bioactivity data


Immobilized Human CXCR4 Full Length Protein-VLP (Cat. No. CX4-H5219) at 5 μg/mL (100 μL/well) can bind Human ulocuplumab, Human IgG4 with a linear range of 1-31 ng/mL (QC tested).

Synonym Name



C-X-C chemokine receptor type 4 is also known as fusin or CD184 (cluster of differentiation 184), CXCR4, CD184, D2S201E, FB22, HM89, HSY3RR, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R or WHIM. CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12), a molecule endowed with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV isolates can use to infect CD4+ T cells. HIV isolates that use CXCR4 are traditionally known as T-cell tropic isolates. Typically, these viruses are found late in infection. It is unclear as to whether the emergence of CXCR4 using HIV is a consequence or a cause of immunodeficiency.CXCR4 is upregulated during the implantation window in natural and hormone replacement therapy cycles in the endometrium, producing, in presence of a human blastocyst, a surface polarization of the CXCR4 receptors suggesting that this receptor is implicated in the adhesion phase of human implantation. SDF-1 and CXCR4 were believed to be a relatively "monogamous" ligand-receptor pair (other chemokines tend to use several different chemokine receptors in a fairly "promiscuous" manner). Recent evidence demonstrates ubiquitin is also a natural ligand of CXCR4. Chronic exposure to THC increased T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes. Drugs that block the CXCR4 receptor appear to be capable of "mobilizing" hematopoietic stem cells into the bloodstream as peripheral blood stem cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Plerixafor SDZ-SID-791; JM-3100; JKL-169; AMD-3100; PLR-001; LM-3100 Approved Genzyme Corp Mozobil, Mobozil, 释倍灵 United States Lymphoma, Non-Hodgkin; Multiple Myeloma Genzyme Corp 2008-12-15 Lymphoma, Non-Hodgkin; Pulmonary Fibrosis; Rejection of organ transplantation; Osteosarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukopenia; Colorectal Neoplasms; Agranulocytosis; Lymphopenia; Multiple Myeloma; Lymphoma; Leukemia, Myeloid, Acute; Pulmonary Disease, Chronic Obstructive; Granulomatous Disease, Chronic; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Anemia, Sickle Cell; Bone metastases; Fanconi Anemia; Pancreatic Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Primary Graft Dysfunction; Warts; WHIM syndrome; Neutropenia; Infections; Wiskott-Aldrich Syndrome; Cystic Fibrosis; Hematopoietic stem cell transplantation (HSCT); Leukemia, Myelogenous, Chronic; Hematologic Neoplasms Details
Motixafortide TN-14003; TF-14016; BL-8040; 4F-Benzoyl-TN14003; BKT-140; GFH-168; 4F-benzoyl-TN-14003 Approved Biokine, Kyoto University APHEXDA United States Hematopoietic stem cell transplantation (HSCT) Biolinerx Ltd 2023-09-08 Multiple Myeloma; Anemia, Sickle Cell; Adenocarcinoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Hematopoietic stem cell transplantation (HSCT); Myeloproliferative Disorders; Myelodysplastic Syndromes; Pancreatic Neoplasms; Hodgkin Disease; Esophageal Neoplasms; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
[68Ga]Pentixafor Phase 3 Clinical The University Of Iowa Lymphoma, B-Cell, Marginal Zone; Cushing Syndrome; Sarcoidosis; Rejection of organ transplantation; Neuroendocrine Tumors; Myocarditis; Central Nervous System Lymphoma; Hyperaldosteronism Details
90Y-Pentixather Phase 2 Clinical University Of Wurzburg, Technical University Of Munich Multiple Myeloma; Central Nervous System Lymphoma Details
177Lu-Pentixather Phase 2 Clinical Technical University Of Munich, Nantes University Hospital, University Of Wurzburg Leukemia; Multiple Myeloma Details
Ulocuplumab MDX-1338; BMS-936564 Phase 2 Clinical Bristol-Myers Squibb Company Leukemia; Solid tumours; Multiple Myeloma; Lymphoma, Follicular; Leukemia, B-Cell; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details
MSX-122 Q-122; WZ-40; MSX-122 Phase 2 Clinical Altiris Therapeutics Solid tumours; Hot Flashes Details
PTX-9908 PTX-9908 Phase 2 Clinical Pertinax Therapeutics Carcinoma, Hepatocellular Details
Plerixafor/Tacrolimus Hydrate MRG-001(MedRegen); AMD3100+FK506 Phase 2 Clinical MedRegen LLC Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Abdominal Injuries; Wounds and Injuries Details
NRP-2945 NNZ-4945; NRP-2945 Phase 2 Clinical Neuren Pharmaceuticals Ltd Epilepsy Details
GPC-100 GPC-100 Phase 2 Clinical GPCR Therapeutics USA Inc Multiple Myeloma Details
4-P-021 4P021; 4-P-021 Phase 2 Clinical 4P-Pharma Ltd, University of Bordeaux, Institut Pasteur De Lille Coronavirus Disease 2019 (COVID-19) Details
CGT-1881 CGT1881; CGT-1881 Phase 2 Clinical Cgenetech(Suzhou China) Co Ltd Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Multiple Myeloma; Lymphoma, Non-Hodgkin Details
LY-2510924 T-134; LY-2510924 Phase 1 Clinical Eli Lilly And Company Leukemia; Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma Details
AGT 103-T AGT 103-T Phase 1 Clinical American Gene Technologies International Inc HIV Infections Details
Balixafortide POL-6326 Phase 1 Clinical Polyphor Ltd Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Multiple Myeloma; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details
JVS-100 JVS-100; SRX-100; ACRX-100; GP-51801; GP51801 Phase 1 Clinical Cleveland Clinic Heart Failure; Ischemia; Surgical Wound; Peripheral Arterial Disease Details
Dociparstat sodium ODSH; CX-01; PGX-100; PGX-ODSH-2013-AML-1 Phase 1 Clinical Paringenix Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Myelodysplastic Syndromes; Protein-Losing Enteropathies; Pulmonary Disease, Chronic Obstructive; Leukemia, Myeloid, Acute; Acute Lung Injury Details
203-Lead Pentixather Phase 1 Clinical National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center Small Cell Lung Carcinoma; Lung Neoplasms Details
212-Lead Pentixather Phase 1 Clinical National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center Small Cell Lung Carcinoma; Lung Neoplasms Details
68Ga-Pentixather 68Ga-Pentixather Phase 1 Clinical Peking Union Medical College Hospital Multiple Myeloma Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) Phase 1 Clinical Sichuan University Multiple Myeloma Details
AD-214 AD-214 Phase 1 Clinical Addpharma Inc, Adalta Ltd Lung Diseases, Interstitial; Gastroesophageal Reflux Details
X-4136 X-4136 Clinical X4 Pharmaceuticals Inc Lymphoma, B-Cell; Uterine Cervical Neoplasms; Melanoma Details
[18F]AlF-NOTA-pentixather Sichuan Provincial People'S Hospital Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message